EU packaging compliance is a slow margin squeeze - IHE is the blunt expression
The Opportunity
The upstream bet is SHORT via pharma proxy (IHE) on the idea that EU compliance and packaging regime tightening transmits into cost, redesign burden, and supply-chain friction. This is not a 'one company blows up' trade - it is a 'small costs become consensus over time' trade, which is exactly why a proxy makes sense.
The Timing
Freshness is 55 and upstream flags that the underlying regulation dates back to 19 December 2024, so the timing edge is not the existence of the rule but the implementation wave (guidance, enforcement phasing, supplier mobilisation). In Mixed 68 conditions, slow-burn stories can underperform fast catalysts; what upgrades timing is a concrete effective-date or enforcement step that forces issuer disclosures.
The Evidence
Upstream validation is unconfirmed, but lack of chatter is not treated as a contradiction. Hydrated evidence is missing in this run, so you cannot audit the originating compliance summary from within this report. The thesis stands or falls on whether compliance phasing produces measurable margin and supply friction that firms must disclose, and that evidence is still not present here.